These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 5933646)

  • 1. Hemagglutination-inhibiting antibody responses in human infections with group B coxsackieviruses.
    Schmidt NJ; Lennette EH; Dennis J
    J Immunol; 1966 Feb; 96(2):311-8. PubMed ID: 5933646
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of antibodies produced in natural and experimental coxsackievirus infections.
    Schmidt NJ; Lennette EH; Dennis J
    J Immunol; 1968 Jan; 100(1):99-106. PubMed ID: 4965800
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibodies against Coxsackie group B viruses using HAI tests in the human sera collected from poona.
    Phadke AR; Niphadkar KB; Deodhare SG
    J Postgrad Med; 1971 Jul; 17(3):103-7. PubMed ID: 5123720
    [No Abstract]   [Full Text] [Related]  

  • 4. Neutralizing, hemagglutination-inhibiting and group complement-fixing antibody responses in human adenovirus infections.
    Schmidt NJ; Lennette EH; King CJ
    J Immunol; 1966 Jul; 97(1):64-74. PubMed ID: 4288350
    [No Abstract]   [Full Text] [Related]  

  • 5. ANTIBODY RESPONSES OF RHESUS (MACACA MULATTA) MONKEYS EXPERIMENTALLY INFECTED WITH COXSACKIEVIRUSES OF GROUP B AND GROUP A, TYPE 9. I. ANTIBODY RESPONSES WITH THE COXSACKIEVIRUS GROUP.
    SCHMIDT NJ; DENNIS J; LENNETTE EH; HO HH; SHINOMOTO TT
    J Immunol; 1965 Jul; 95():54-69. PubMed ID: 14322580
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunological studies with group B arthropod-borne viruses. VI. Hemagglutination-inhibiting antibody responses to 17D yellow fever vaccine in human subjects with different degrees of complexity of pre-vaccination group B virus experience.
    Hatgi JN; Wisseman CL; Rosenzweig EC; Harrington BR; Kitaoka M
    Am J Trop Med Hyg; 1966 Jul; 15(4):601-10. PubMed ID: 5941178
    [No Abstract]   [Full Text] [Related]  

  • 7. [The neutralizing antibody in serum, 2 years after infection with Coxsackie B5 and A9 viruses].
    Nakao T; Hinuma Y
    Nihon Shonika Gakkai Zasshi; 1965 Jul; 69(7):640-2. PubMed ID: 5894386
    [No Abstract]   [Full Text] [Related]  

  • 8. [Naturally acquired immunity to enteroviruses in a group of inhabitants of Riyad (Saudi Arabia)].
    Lippi M; Sebastiani A; el-Mutabakani H
    Arch Ital Sci Med Trop Parassitol; 1968; 49(9):243-50. PubMed ID: 5718731
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunological response of the newborn infant to Coxsackie B-4 infection.
    Sieber OF; Kilgus AH; Fulginiti VA; Pearlman D
    Pediatrics; 1967 Sep; 40(3):444-6. PubMed ID: 6036193
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis.
    Holzmann H; Kundi M; Stiasny K; Clement J; McKenna P; Kunz C; Heinz FX
    J Med Virol; 1996 Jan; 48(1):102-7. PubMed ID: 8825718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Presence of neutralizing antibodies against Coxsackie virus and Echoviruses 9,11 and 12 in subjects of Accra (Ghana)].
    Russo V; D'Arrigo C; Rosei L
    Arch Ital Sci Med Trop Parassitol; 1968; 49(5):145-52. PubMed ID: 5715929
    [No Abstract]   [Full Text] [Related]  

  • 12. Enterovirus infections with beta-cell tropic strains are frequent in siblings of children diagnosed with type 1 diabetes children and in association with elevated levels of GAD65 antibodies.
    Frisk G; Tuvemo T
    J Med Virol; 2004 Jul; 73(3):450-9. PubMed ID: 15170642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Coxsackie viruses in Rumania. II. Immuno-serological studies].
    Arion R; Buimovici-Klein E; Slobodă E; Dinculescu M
    Stud Cercet Inframicrobiol; 1968; 19(5):333-42. PubMed ID: 5718078
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of rivanol treatment for removal from sera of nonspecific inhibitors of enterovirus and reovirus hemagglutination.
    Styk B; Schmidt NJ; Dennis J
    Am J Epidemiol; 1968 Nov; 88(3):398-405. PubMed ID: 4301611
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistance of neutralizing antibody to Coxsackievirus B5 following aseptic meningitis.
    Hinuma Y; Nakao T
    Jpn J Med Sci Biol; 1965 Jun; 18(3):157-60. PubMed ID: 5294928
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative study of haemagglutination-inhibiting-antibody and neutralising antibody in sera of cases of smallpox.
    Sarkar JK; Chatterjee SN; Mitra AC; Mandal A
    Bull Calcutta Sch Trop Med; 1966 Jan; 14(1):4-5. PubMed ID: 5961043
    [No Abstract]   [Full Text] [Related]  

  • 17. ECHO 11 VIRUS INFECTIONS ASSOCIATED WITH EXANTHEMS.
    CHERRY JD; LERNER AM; KLEIN JO; FINLAND M
    Pediatrics; 1963 Oct; 32():509-16. PubMed ID: 14069092
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental infection of beagle dogs with Coxsackievirus type B1.
    Lundgren DL; Hobbs CH; Clapper WE
    Am J Vet Res; 1971 Apr; 32(4):609-13. PubMed ID: 5110117
    [No Abstract]   [Full Text] [Related]  

  • 19. Mercaptoethanol-sensitive neutralizing-antibody in natural infection with coxsackievirus B5.
    Ohta-Hatano R; Hinuma Y
    Proc Soc Exp Biol Med; 1966 Jul; 122(3):725-9. PubMed ID: 5918940
    [No Abstract]   [Full Text] [Related]  

  • 20. Detection of IgM antibodies against coxsackie B viruses by a western blot technique.
    del Rosario Zuñiga M; Reichardt J; Braun W; Weber B; Doerr HW
    Acta Virol; 1993 Feb; 37(1):1-10. PubMed ID: 8105643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.